THERAPY DOSSIER · th-6987c7dcd5e7

Myeloid zinc finger protein 1 (MZF1) siRNA, and recombinant adeno-associated virus 5 expressing full-length MZF1

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25630025 ↗2015Reported benefit

Dorsal root ganglion myeloid zinc finger protein 1 contributes to neuropathic pain after peripheral nerve trauma.

RatCrushPeripheral-nerve crushSprague-DawleyMalen = n=5 rats per siRNA group in the maintenance experimentMicroinjection into the injured dorsal root ganglionTargeting both the initiation and maintenance phases after chronic constriction…

Model: Chronic constriction injury of the sciatic nerve

Dorsal root ganglion MZF1 siRNA attenuated initiation and maintenance of mechanical, cold and thermal hypersensitivity without affecting locomotor function or basal responses, while MZF1 overexpression produced hypersensitivity in naive rats. MZF1 mediated the injury-induced loss of Kv1.2 and incre…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…